Bachem Holding AG has successfully raised approximately CHF 108 million ($116 million) through the placement of 1’250’000 new registered shares (the “New Shares”) at a placement price of CHF 86.50 per New Share.

 

"The need for peptide & oligonucleotide therapeutics production (TIDES) continues to increase as these molecules are increasingly used to tackle health issues like endocrine disorders, diabetes, obesity and cardiovascular diseases. With today’s successful share placement, Bachem will continue investing in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies." said Thomas Meier, CEO, Bachem.

 

The share capital of Bachem will increase from CHF 737’500 to CHF 750’000 through the issuance of 1’250’000 New Shares each with a par value of CHF 0.01 against cash contributions. The New Shares carry full dividend rights for the fiscal year 2022.

 

The New Shares are expected to be listed and admitted to trading on SIX Swiss Exchange on March 13, 2023. Payment and settlement are expected to take place on March 14, 2023.

 

Peter Grogg, founder and honorary Chairman, as well as the holding company controlled by him, will continue to hold a majority of the share capital in Bachem and both entered into a 90-day lock-up period. Bachem also agreed to a 90-day lock-up period after the listing of the New Shares, subject to certain customary exceptions.

 

UBS acted as Sole Global Coordinator and Bookrunner in the context of the capital increase.